Summary
The epidermal growth factor receptor (EGFR) plays an important role in the development and progression of prostate cancer and its overexpression is associated with decreased survival. With progression, prostate cancer cells switch from epidermal growth factor (EGF) to transforming growth factor α (TGF-α) synthesis, which contributes to autocrine growth and unrestrained proliferation. To define the molecular mechanisms involved in the regulation of EGFR expression by EGF and TGF-α we studied three human prostate cancer cell lines, androgen-responsive (LNCaP) and -unresponsive (DU145 and PC3). Here we show that TGF-α stabilized EGFR mRNA two- to threefold in all three cell lines, whilst EGF stabilized EGFR mRNA ~ twofold in LNCaP and DU145 cells, but not in PC3 cells. Both ligands increased EGFR transcription in LNCaP and DU145 cells, with less effect in PC3 cells. In all three cell lines EGF reduced total EGFR protein levels more than TGF-α, but this was associated with a greater increase in de novo protein synthesis with EGF compared to TGF-α. Only EGF, however, shortened EGFR protein stability (half-life decreased from 5 h to 120 min), resulting in rapid disappearance of newly synthesized EGFR protein. Both ligands increased total LNCaP and DU145 cell numbers. These studies demonstrate that the EGF- and TGF-α-induced upregulation of EGFR mRNA and protein in human prostate cancer cell lines is complex and occurs at multiple, transcriptional and post-transcriptional levels. Taken together, these data provide novel insight into the molecular mechanisms by which TGF-α would preferentially maintain an autocrine loop in human prostate cancer cells. Furthermore, this work suggests that in human prostate cancer cells ligand-specific differential intracellular trafficking of the EGFR plays a major role in regulating its expression.
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Ausubel, F. M., Brent, R., Kingston, R. E., Moore, D. D., Seidman, J. G., Smith, J. A. & Struhl, K. (eds) (1994). Identification of newly transcribed RNA. In Current Protocols in Molecular Biology. Wiley: Toronto
Beguinot, L., Lyall, R. M., Willingham, M. C. & Pastan, I. (1984). Down-regulation of the epidermal growth factor receptor in KB cells is due to receptor internalisation and subsequent degradation in lysomes. Proc Natl Acad Sci USA 81: 2384–2388.
Beguinot, L., Hanover, J. A., Ito, S., Richert, N. D., Willingham, M. C. & Pastan, I. (1985). Phorbal esters induce transient internalisation without degradation of unoccupied epidermal growth factor receptors. Proc Natl Acad Sci USA 82: 2774–2778.
Bilous, M., Milliken, J. & Mathijs, J. M. (1992). Immunocytochemistry and in situ hybridization of epidermal growth factor receptor and relation to prognostic factors in breast cancer. Eur J Cancer 28: 1033–1037.
Brass, A. L., Barnard, J., Patai, B. L., Salvi, D. & Rukstalis, D. B. (1995). Androgen up-regulates growth factor receptor expression and binding affinity in PC3 cell lines expressing the human androgen receptor. Cancer Res 55: 3197–3203.
Burden, S. & Yarden, Y. (1997). Neuregulins and their receptors: a versatile signaling module in organogenesis and oncogenesis. Neuron 18: 847–855.
Byrne, R. L., Leung, H. & Neal, D. E. (1996). Peptide growth factors in the prostate as mediators of stromal epithelial interaction. Br J Urol 77: 627–633.
Carruba, G., Leake, R. E., Rinaldi, F., Chalmers, D., Comito, L., Sorci, C., Pavone-Macaluso, M. & Castagnetta, L. A. M. (1994). Steroid-growth factor interaction in human prostate cancer. Part 1: Short-term effects of transforming growth factors on growth of human prostate cancer cells. Steroids 59: 412–420.
Ching, K. Z., Ramsey, E., Pettigrew, N., D’Cuhna, R., Jason, M. & Dodd, J. G. (1993). Expression of mRNA for epidermal growth factor, transforming growth factor-alpha and their receptor in human prostate tissue and cell lines. Mol Cell Biochem 126: 151–158.
Clark, A. J., Ishii, S., Richert, N., Merlino, G. T. & Pastan, I. (1985). Epidermal growth factor stimulates the expression of its own receptor. Proc Natl Acad Sci USA 82: 8374–8378.
Connolly, J. M. & Rose, D. P. (1990). Production of epidermal growth factor and transforming growth factor-α by androgen-responsive LNCaP human prostate cancer cell line. Prostate 16: 209–218.
Connolly, J. M. & Rose, D. P. (1991). Autocrine regulation of DU145 human prostate cancer cell growth by epidermal growth factor-related polypeptides. Prostate 19: 173–180.
Davies, P. & Eaton, C. (1989). Binding of epidermal growth factor by human normal, hypertrophic, and carcinomatous prostate. Prostate 14: 123–132.
Decker, C. J. & Parker, R. (1994). Mechanisms of mRNA degradation in eukaryotes. Trends Biochem Sci 19: 336–340.
Earp, H. S., Austin, K. S., Blaisdall, J., Rubin, R. A., Nelson, K. G., Lee, L. W. & Grisham, J. W. (1986). Epidermal growth factor stimulates EGF receptor synthesis. J Biol Chem 261: 4777–4780.
Ebner, R. & Derynck, R. (1991). Epidermal growth factor and transforming growth factor-alpha: differential intracellular routing and processing of ligand-receptor complexes. Cell Regul 2: 599–612.
Ennis, B. W., Valverius, E. M., Bates, S. E., Lippman, M. E., Bellot, F., Kris, R., Schlessinger, J., Masui, H., Goldenberg, A., Mendelsohn, J. & Dickson, R. B. (1989). Anti-epidermal growth factor receptor antibodies inhibit the autocrine-stimulated growth of MDA468 human breast cancer cells. Mol Endocrinol 3: 1830–1838.
Fernandez-Pol, J. A., Hamilton, P. D. & Klos, D. J. (1989). Transcriptional regulation of proto-oncogene expression by epidermal growth factor, transforming growth factor β1, and triiodothyronine in MDA468 cells. J Biol Chem 264: 4151–4156.
French, A. R., Tadaki, D. K., Niyogi, S. K. & Lauffenburger, D. A. (1995). Intracellular trafficking of epidermal growth factor family ligands is directly influenced by the pH sensitivity of the receptor/ligand interaction. J Biol Chem 270: 4334–4340.
Glynne-Jones, E., Goddard, L. & Harper, M. E. (1996). Comparative analysis of mRNA and protein expression for epidermal growth factor receptor and ligands relative to the proliferative index in human prostate tissue. Hum Pathol 27: 688–694.
Greenberg, M. E. & Belasco, J. G. (1993). Control of degradation of labile protooncogene and lymphokine mRNAs. In Control of mRNA Stability, Belasco JG and Brawerman G (eds), pp. 199–218. Academic Press: London
Gullick, W. J. (1991). Prevalence of aberrant expression of the epidermal growth factor receptor in human cancers. Br Med Bull 47: 87–96.
Hanover, J. A., Beguinot, L., Willingham, M. C. & Pastan, I. H. (1985). Transit of receptors for epidermal growth factor and transferrin through clathrincoated pits. Analysis of the kinetics of receptor entry. J Biol Chem 260: 15938–15945.
Hofer, D. R., Sherwood, E. R., Bromberg, W. D., Mendelsohn, J. & Lee, C. (1991). Autonomous growth of androgen-independent human prostatic carcinoma cells: role of transforming growth factor α. Cancer Res 51: 2780–2785.
Jarrard, D. F., Blitz, B. F., Smith, R. C., Patai, B. L. & Rukstalis, D. B. (1994). Effect of epidermal growth factor on prostate cancer cell line PC3 growth and invasion. Prostate 24: 46–53.
Jinno, Y., Merlino, G. T. & Pastan, I. (1988). A novel effect of EGF on mRNA stability. Nucl Acid Res 16: 4957–4966.
Kawamoto, T., Sato, J. D., Le, A., Polikoff, J., Sato, G. H. & Mendelsohn, J. (1983). Growth stimulation of A431 cells by epidermal growth factor: identification of high affinity receptors for epidermal growth factor by an anti-receptor monoclonal antibody. Proc Natl Acad Sci USA 80: 1337–1341.
Kesavan, P., Mukhopadhyay, S., Murphy, S., Rengaraju, M., Lazar, M. A. & Das, M. (1991). Thyroid hormone decreases the expression of epidermal growth factor receptor. J Biol Chem 266: 10282–10286.
Kudlow, J. E., Cheung, C-YM & Bjorge, J. D. (1986). Epidermal growth factor stimulates its own receptor in a human breast cancer cell line. J Biol Chem 261: 4134–4138.
Kurten, R. C., Cadena, D. L. & Gill, G. N. (1996). Enhanced degradation of EGF receptors by a sorting nexin, SNX1. Science 272: 1008–1010.
Lifshitz, A., Lazar, C. S., Buss, J. E. & Gill, G. N. (1983). Analysis of morphology and receptor metabolism in clonal variant A431 cells with differing growth responses to epidermal growth factor. J Cell Physiol 115: 235–242.
Lippman, M. E. (1993). The development of biological therapies for breast cancer. Science 259: 631–632.
Liu, X-H, Wiley, H. S. & Miekle, A. W. (1993). Androgens regulate proliferation of human prostate cancer cells in culture by increasing transforming growth factor-α and epidermal growth factor/TGF-α receptor. J Clin Endocrinol Metab 77: 1472–1478.
Maddy, S. Q., Chisholm, G. D., Busuttil, A. & Habib, F. K. (1989). Epidermal growth factor receptors in human prostate cancer: correlation with histological differentiation of the tumor. Br J Cancer 60: 41–44.
Mendelsohn, J. (1992). Epidermal growth factor receptor as a target for therapy with antireceptor monoclonal antibodies. J Natl Cancer Inst Monogr 13: 125–131.
Modjtahedi, H. & Dean, C. (1994). The receptor for EGF and its ligands: expression, prognostic value and target for therapy in cancer. Int J Oncol 4: 277–296.
Morris, G. L. & Dodd, J. G. (1990). Epidermal growth factor receptor mRNA levels in human prostatic tumors and cell lines. J Urol 143: 1272–1274.
Nomura, A. M. Y. & Kolonel, N. (1991). Prostate cancer: a current perspective. Am Epidemiol 18: 200–226.
Peltz, S. W. & Jacobson, A. (1992). Regulation of mRNA turnover in eukaryotic cells. Curr Opin Cell Biol 4: 979–983.
Prewett, M., Rockwell, P., Rockwell, R. F., Giorgio, N. A., Mendelsohn, J., Scher, H. I. & Goldstein, N. I. (1997). The biologic effects of C225, a chimeric monoclonal antibody to the EGFR, on human prostate carcinoma. J Immunother 19: 419–427.
Sachs, A. B. (1993). Messenger RNA degradation in eukaryotes. Cell 74: 413–421.
Schuurmans, A. L. G., Bolt, J. & Mulder, E. (1988). Androgens stimulate both growth rate and epidermal growth factor receptor activity of the human prostate tumor cell line LNCaP. Prostate 12: 55–63.
Schuurmans, A. L. G., Bolt, J., Veldscholte, J. & Mulder, E. (1991). Regulation of growth of LNCaP human prostate tumor cells by growth factors and steroid hormones. J Steroid Biochem Molec Biol 40: 193–197.
Steiner, M. S. (1993). Role of peptide growth factors in the prostate: a review. Urology 42: 99–110.
Steiner, M. S. & Barrack, E. R. (1992). Transforming growth factor β-1 overproduction in prostate cancer: effects of growth in vivo and in vitro. Mol Endocrinol 6: 15–25.
Tilbrook, P. A., Bittorf, T., Busfield, S. J., Chappell, D. & Klinken, S. P. (1996). Disrupted signalling in a mutant J2E cell line that shows enhanced viability, but does not proliferate or differentiate, with erythropoietin. J Biol Chem 271: 3453–3459.
Todaro, G. J., Fryling, C. & DeLarco, J. E. (1979). Transforming growth factors produced by certain human tumor cells: polypeptides that interact with epidermal growth factor receptors. Proc Natl Acad Sci USA 77: 5258–5262.
Traish, A. M. & Wotiz, H. H. (1987). Prostatic epidermal growth factor receptors and their regulation by androgens. Endocrinology 121: 1461–1467.
Turkeri, L. N., Sakr, W. A., Wykes, S. M., Grignon, D. J., Pontes, J. E. & Macoska, J. A. (1994). Comparative analysis of epidermal growth factor receptor gene expression and protein product in benign, premalignant, and malignant prostate tissue. Prostate 25: 199–205.
Tzahar, E., Pinkas-Kramarski, R., Moyer, J., Klapper, L. N., Alroy, I., Levkowitz, G., Shelly, M., Henis, S., Eisenstein, M., Ratzkin, B. J., Sela, M., Andrews, G. C. & Yarden, Y. (1997). Bivalence of EGF-like ligands drives the ErbB signaling network. EMBO J 16: 4938–4950.
Vieira, A. V., Lamaze, C. & Schmid, S. L. (1996). Control of EGF receptor signalling by clathrin-mediated endocytosis. Science 274: 2086–2089.
Waterman, H., Sabanai, I., Geiger, B. & Yarden, Y. (1998). Alternative intracellular routing of erbB receptors may determine signaling potency. J Biol Chem 273: 13819–13827.
Wilding, G., Valverius, E., Knabbe, C. & Gelmann, E. P. (1989). Role of transforming growth factor-α in human prostate cancer cell growth. Prostate 15: 1–12.
Wiley, H. S., Herbst, J. J., Walsh, B. J., Lauffenburger, D. A., Rosenfeld, M. G. & Gill, G. N. (1991). The role of tyrosine kinase activity in endocytosis, compartmentation, and down-regulation of the epidermal growth factor receptor. J Biol Chem 266: 11083–11094.
Xie, H., Turner, T., Wang, M-H, Singh, R. K., Siegal, G. P. & Wells, A. (1995). In vitro invasiveness of DU145 human prostate carcinoma cells is modulated by EGF receptor-mediated signals. Clin Exp Metastasis 13: 407–419.
Zhau, H. Y., Chang, S-M, Chen, B-Q, Wang, Y., Zhang, H., Kao, C., Sang, Q. A., Pathak, S. J. & Chung, L. W. (1996). Androgen-repressed phenotype in prostate cancer. Proc Natl Acad Sci USA 93: 15152–15157.
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Seth, D., Shaw, K., Jazayeri, J. et al. Complex post-transcriptional regulation of EGF-receptor expression by EGF and TGF-α in human prostate cancer cells. Br J Cancer 80, 657–669 (1999). https://doi.org/10.1038/sj.bjc.6690407
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bjc.6690407
Keywords
This article is cited by
-
Targeted in vivo delivery of EGFR siRNA inhibits ovarian cancer growth and enhances drug sensitivity
Scientific Reports (2016)
-
Bax expression remains unchanged following antisense treatment directed against BCL-2
Medical Oncology (2011)
-
Analytical validation of the GeXP analyzer and design of a workflow for cancer-biomarker discovery using multiplexed gene-expression profiling
Analytical and Bioanalytical Chemistry (2009)
-
Multi-level gene expression profiles affected by thymidylate synthase and 5-fluorouracil in colon cancer
BMC Genomics (2006)